XEOMEEN® 100 unidades is a botulinum toxin type A product that is used to block neuromuscular transmission, thereby reducing muscle activity in targeted areas. It contains a purified neurotoxin free of complexing proteins, offering a lower risk of antibody formation compared to some alternatives.
- Active ingredient: IncobotulinumtoxinA (botulinum toxin type A)
- Dosage strength: 100 units per vial (lyophilized powder)
- Form: Injectable solution after reconstitution
- Presentation: Clear, colorless solution once reconstituted with saline
- Mechanism: Inhibits acetylcholine release at neuromuscular junctions
- Onset of action: Begins within 3–7 days
- Duration of effect: Typically lasts up to 12–16 weeks
XEOMEEN (XEOMIN®) 100u – Unique Technology
XEOMEEN® is formulated using XTRACT Technology, which eliminates accessory proteins that are not required for therapeutic action. This results in a “naked” neurotoxin, potentially reducing the immunogenic response over repeated treatments.
- Purified botulinum toxin with no complexing proteins
- Lower likelihood of neutralizing antibody formation
- Does not require refrigeration prior to reconstitution
- Room-temperature stable up to 3 years before opening
- Offers consistent dosing and reliable clinical response
XEOMEEN (XEOMIN®) 100u – Indications
XEOMEEN® is indicated for both therapeutic and aesthetic uses in adults. In the aesthetic field, it is primarily used to treat dynamic facial wrinkles such as glabellar lines.
- Aesthetic indications:
- Moderate to severe glabellar frown lines (between the eyebrows)
- Therapeutic indications:
- Cervical dystonia (torticollis)
- Blepharospasm
- Upper limb spasticity post-stroke
- Sialorrhea (excessive drooling)
- Not indicated in children or adolescents under 18 years for cosmetic purposes
- Only to be used by trained healthcare professionals
XEOMEEN (XEOMIN®) 100u – Dosage and Administration
XEOMEEN® must be reconstituted with 0.9% sodium chloride solution before administration. The dosage depends on the indication and muscle mass of the patient.
- Glabellar lines: 20 units total (5 units per injection in 5 sites)
- Cervical dystonia: 120–500 units per session, individualized
- Blepharospasm: 25–50 units per eye
- Sialorrhea: 100 units into salivary glands (parotid and submandibular)
- Administration route: Intramuscular (IM) or intraglandular
- Injection intervals: Not more frequent than every 12 weeks
- Use immediately after reconstitution or store refrigerated up to 24 hours
XEOMEEN (XEOMIN®) 100u – Side Effects and Precautions
Side effects depend on the injection site and dosage. Most are mild to moderate and transient, but serious adverse effects can occur, particularly if the toxin spreads beyond the target area.
- Common side effects:
- Headache, ptosis (drooping eyelids), dry mouth, muscle weakness
- Less common:
- Vision disturbances, dysphagia, neck pain
- Rare but serious:
- Hypersensitivity reactions, respiratory difficulties, general muscle weakness
- Precautions:
- Avoid in patients with neuromuscular disorders
- Caution in those using aminoglycosides or muscle relaxants
- Avoid if pregnant or breastfeeding
- Not recommended for use with other botulinum toxin products simultaneously
XEOMEEN (XEOMIN®) 100u – Clinical Studies and Real-World Outcomes
XEOMEEN® has been studied in multiple clinical trials, confirming its safety and efficacy in both aesthetic and therapeutic indications. It is recognized for its comparable results to Botox® in clinical efficacy and duration.
- Glabellar lines: Significant improvement within 7 days
- Duration of action: Lasts 12–16 weeks in most patients
- Therapeutic efficacy shown in dystonia and spasticity trials
- High patient satisfaction and lower immunogenicity
- Studies report similar efficacy to onabotulinumtoxinA (Botox) with non-inferior duration
XEOMEEN (XEOMIN®) 100u – Drug Interactions
Like all botulinum toxins, XEOMEEN® should not be combined with other agents affecting neuromuscular transmission. This can increase the risk of side effects such as muscle weakness or difficulty breathing.
- Avoid with:
- Aminoglycoside antibiotics (e.g., gentamicin)
- Muscle relaxants
- Anticholinergic medications
- Inform healthcare provider about:
- Any history of neuromuscular disorders
- Concurrent treatments with other botulinum toxins
XEOMEEN (XEOMIN®) 100u – Post-Treatment Care
After treatment, patients should avoid manipulating the injection site and monitor for potential adverse effects. Providers should inform patients about warning signs that require medical attention.
- Avoid massaging or rubbing the injection site for 24 hours
- Remain upright for at least 4 hours after injection
- Do not exercise or lie down immediately post-treatment
- Monitor for signs of:
- Difficulty breathing or swallowing
- Muscle weakness
- Allergic reaction (rash, swelling, itching)
- Follow-up treatment may be required after 12–16 weeks